Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-74856665 + venetoclax
- Development stage
- Unknown
- Lead developer
- Janssen Research & Development
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**JNJ-74856665 + venetoclax** is an investigational combination therapy evaluated in the treatment of hematological malignancies, primarily *acute myeloid leukemia (AML)*, *myelodysplastic syndromes (MDS)*, and *chronic myelomonocytic leukemia (CMML)*. JNJ-74856665 is an orally bioavailable, potent, and selective small molecule inhibitor of *dihydroorotate dehydrogenase (DHODH)*, which binds to the enzyme’s ubiquinone binding site and promotes leukemic cell differentiation, induces cell cycle arrest, and apoptosis[1][2][3][8]. Venetoclax is a selective inhibitor of *BCL-2*, a protein that inhibits apoptosis; its blockade restores programmed cell death in malignant cells[1][7]. The combination is being studied to assess safety, tolerability, dose escalation, and efficacy in relapsed/refractory and newly diagnosed AML and MDS[1][3][7].
- Other names
- JNJ-74856665 + venetoclax
02
Targets
DHODH (Dihydroorotate dehydrogenase (quinone), mitochondrial)
Beyond the preview
Go deeper on JNJ-74856665 + venetoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-74856665 + venetoclax.